| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial V Heinemann, LF von Weikersthal, T Decker, A Kiani, U Vehling-Kaiser, ... The lancet oncology 15 (10), 1065-1075, 2014 | 1966 | 2014 |
| Migrating cancer stem cells—an integrated concept of malignant tumour progression T Brabletz, A Jung, S Spaderna, F Hlubek, T Kirchner Nature Reviews Cancer 5 (9), 744-749, 2005 | 1713 | 2005 |
| Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment T Brabletz, A Jung, S Reu, M Porzner, F Hlubek, LA Kunz-Schughart, ... Proceedings of the National Academy of Sciences 98 (18), 10356-10361, 2001 | 1394 | 2001 |
| Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia M Tartaglia, CM Niemeyer, A Fragale, X Song, J Buechner, A Jung, ... Nature genetics 34 (2), 148-150, 2003 | 1189 | 2003 |
| β-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer T Brabletz, A Jung, S Dag, F Hlubek, T Kirchner The American journal of pathology 155 (4), 1033-1038, 1999 | 894 | 1999 |
| Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β-catenin T Brabletz, F Hlubek, S Spaderna, O Schmalhofer, E Hiendlmeyer, A Jung, ... Cells tissues organs 179 (1-2), 56-65, 2005 | 697 | 2005 |
| The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer S Spaderna, O Schmalhofer, M Wahlbuhl, A Dimmler, K Bauer, A Sultan, ... Cancer research 68 (2), 537-544, 2008 | 667 | 2008 |
| High macrophage infiltration along the tumor front correlates with improved survival in colon cancer J Forssell, A Öberg, ML Henriksson, R Stenling, A Jung, R Palmqvist Clinical cancer research 13 (5), 1472-1479, 2007 | 631 | 2007 |
| A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer S Spaderna, O Schmalhofer, F Hlubek, G Berx, A Eger, S Merkel, A Jung, ... Gastroenterology 131 (3), 830-840, 2006 | 560 | 2006 |
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of … S Stintzing, DP Modest, L Rossius, MM Lerch, LF von Weikersthal, ... The Lancet Oncology 17 (10), 1426-1434, 2016 | 453 | 2016 |
| Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer J Neumann, E Zeindl-Eberhart, T Kirchner, A Jung Pathology-Research and Practice 205 (12), 858-862, 2009 | 430 | 2009 |
| CD133 expression is an independent prognostic marker for low survival in colorectal cancer D Horst, L Kriegl, J Engel, T Kirchner, A Jung British journal of cancer 99 (8), 1285-1289, 2008 | 415 | 2008 |
| KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program J Van Krieken, A Jung, T Kirchner, F Carneiro, R Seruca, FT Bosman, ... Virchows Archiv 453, 417-431, 2008 | 387 | 2008 |
| Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis T Jamieson, M Clarke, CW Steele, MS Samuel, J Neumann, A Jung, ... The Journal of clinical investigation 122 (9), 3127-3144, 2012 | 382 | 2012 |
| Nuclear overexpression of the oncoprotein β-catenin in colorectal cancer is localized predominantly at the invasion front T Brabletz, A Jung, K Hermann, K Günther, W Hohenberger, T Kirchner Pathology-Research and Practice 194 (10), 701-704, 1998 | 377 | 1998 |
| Clinical relevance of EGFR-and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR V Heinemann, S Stintzing, T Kirchner, S Boeck, A Jung Cancer treatment reviews 35 (3), 262-271, 2009 | 352 | 2009 |
| Outcome according to KRAS-, NRAS-and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO … DP Modest, I Ricard, V Heinemann, S Hegewisch-Becker, W Schmiegel, ... Annals of Oncology 27 (9), 1746-1753, 2016 | 285 | 2016 |
| Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer D Horst, L Kriegl, J Engel, T Kirchner, A Jung Cancer investigation 27 (8), 844-850, 2009 | 272 | 2009 |
| The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear β-catenin, cyclin D1, and p16INK4A and is a region of low proliferation A Jung, M Schrauder, U Oswald, C Knoll, P Sellberg, R Palmqvist, ... The American journal of pathology 159 (5), 1613-1617, 2001 | 267 | 2001 |
| Expression of nuclear β-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas T Brabletz, K Herrmann, A Jung, G Faller, T Kirchner The American journal of pathology 156 (3), 865-870, 2000 | 260 | 2000 |
